Aberdeen Asset Management’s Biogen BIIB Stock Holding History

Aberdeen Asset Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$31.1M	Buy	114,574 +7,879	+7%	+$2.08M	0.1%	187
2017 Q1	$29.2M	Buy	106,695 +12,753	+14%	+$3.61M	0.1%	188
2016 Q4	$26.6M	Sell	93,942 -4,313	-4%	-$1.28M	0.1%	185
2016 Q3	$30.8M	Sell	98,255 -2,836	-3%	-$840K	0.11%	150
2016 Q2	$24.4M	Sell	101,091 -2,700	-3%	-$712K	0.09%	172
2016 Q1	$27M	Sell	103,791 -13,095	-11%	-$3.46M	0.1%	145
2015 Q4	$32.4M	Buy	116,886 +7,820	+7%	+$2.25M	0.11%	127
2015 Q3	$31.8M	Buy	109,066 +5,884	+6%	+$1.94M	0.11%	114
2015 Q2	$41.7M	Buy	103,182 +1,773	+2%	+$712K	0.12%	97
2015 Q1	$42.8M	Sell	101,409 -5,765	-5%	-$2.27M	0.12%	98
2014 Q4	$36.4M	Sell	107,174 -13,669	-11%	-$4.42M	0.09%	120
2014 Q3	$40M	Buy	120,843 +11,740	+11%	+$3.87M	0.09%	135
2014 Q2	$34.4M	Buy	109,103 +84,236	+339%	+$25.4M	0.07%	161
2014 Q1	$7.6M	Sell	24,867 -200	-0.8%	-$63.5K	0.02%	144
2013 Q4	$6.96M	Hold	25,067	–	–	0.02%	151
2013 Q3	$6.04M	Sell	25,067 -2,380	-9%	-$533K	0.02%	152
2013 Q2	$5.91M	Buy	+27,447	New	+$5.86M	0.02%	154

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Aberdeen Asset Management's BIIB Position: Q2 2017 in Review

Aberdeen Asset Management increased its Biogen (BIIB) stake by 7.4% in Q2 2017, buying an estimated $2.08M and bringing the position to 114,574 shares worth $31.1M. The position accounts for 0.1% of the portfolio, ranked #187.

Aberdeen Asset Management first reported a position in BIIB in Q2 2013 and has held it in 17 quarters since. The position peaked at $42.8M in Q1 2015. 992 funds tracked by Wall St. Rank hold BIIB as of Q2 2017.

Aberdeen Asset Management held 114,574 shares of Biogen worth $31.1M as of Q2 2017.
Aberdeen Asset Management bought 7,879 Biogen shares in Q2 2017, an estimated $2.08M.
Biogen made up 0.1% of Aberdeen Asset Management's portfolio in Q2 2017, its #187 holding.
Aberdeen Asset Management first reported a position in Biogen in Q2 2013 and has held it in 17 quarters since.
Aberdeen Asset Management's Biogen position peaked at $42.8M in Q1 2015.
992 funds tracked by Wall St. Rank held Biogen as of Q2 2017.

Based on Aberdeen Asset Management's 13F filing for Q2 2017, filed 10 Aug 2017.